US 12,133,894 B2
Compositions and methods for delivery of RNA
Amit Khandhar, Issaquah, WA (US); Steven Reed, Bellevue, WA (US); Malcolm Duthie, Sammamish, WA (US); Jesse Erasmus, Port Orchard, WA (US); Darrick Carter, Seattle, WA (US); and Bryan J. Berube, Issaquah, WA (US)
Assigned to HDT Bio Corp., Seattle, WA (US)
Filed by HDT Bio Corp., Seattle, WA (US)
Filed on Dec. 20, 2023, as Appl. No. 18/390,700.
Application 18/390,700 is a continuation of application No. 18/357,280, filed on Jul. 24, 2023, granted, now 11,896,677.
Application 18/357,280 is a continuation of application No. 17/839,574, filed on Jun. 14, 2022, granted, now 11,752,218, issued on Sep. 12, 2023.
Application 17/839,574 is a continuation of application No. 17/702,730, filed on Mar. 23, 2022, granted, now 11,433,142, issued on Sep. 6, 2022.
Application 17/702,730 is a continuation of application No. 17/523,457, filed on Nov. 10, 2021, granted, now 11,318,213, issued on May 3, 2022.
Application 17/523,457 is a continuation of application No. PCT/US2021/019103, filed on Feb. 22, 2021.
Claims priority of provisional application 62/993,307, filed on Mar. 23, 2020.
Claims priority of provisional application 63/054,754, filed on Jul. 21, 2020.
Prior Publication US 2024/0115728 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/69 (2017.01); A61K 9/107 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 31/713 (2006.01); A61K 39/215 (2006.01); A61K 39/39 (2006.01); A61K 47/02 (2006.01); A61K 47/44 (2017.01); A61K 49/18 (2006.01); A61P 31/14 (2006.01); C07K 14/165 (2006.01); C12N 15/86 (2006.01); C12N 15/88 (2006.01); A61K 39/00 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/54 (2017.01); B82Y 5/00 (2011.01); B82Y 25/00 (2011.01); B82Y 30/00 (2011.01); B82Y 40/00 (2011.01)
CPC A61K 47/6907 (2017.08) [A61K 9/1075 (2013.01); A61K 9/127 (2013.01); A61K 9/5115 (2013.01); A61K 9/5123 (2013.01); A61K 31/7105 (2013.01); A61K 31/711 (2013.01); A61K 31/713 (2013.01); A61K 39/215 (2013.01); A61K 39/39 (2013.01); A61K 47/02 (2013.01); A61K 47/44 (2013.01); A61K 47/6911 (2017.08); A61K 47/6923 (2017.08); A61K 49/183 (2013.01); A61K 49/1833 (2013.01); A61P 31/14 (2018.01); C07K 14/165 (2013.01); C12N 15/86 (2013.01); C12N 15/88 (2013.01); A61K 2039/55555 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/547 (2017.08); B82Y 5/00 (2013.01); B82Y 25/00 (2013.01); B82Y 30/00 (2013.01); B82Y 40/00 (2013.01); C12N 2770/36143 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A composition, wherein the composition comprises:
DNA molecules, wherein the DNA molecules comprise a sequence encoding an antigen; and
lipid nanoparticles, wherein noncomplexed lipid nanoparticles are characterized as having a z-average diameter particle size measurement of about 20 nm to about 60 nm when measured using dynamic light scattering, and wherein the lipid nanoparticles comprise:
a surface comprising cationic lipids; and
a hydrophobic core, wherein the hydrophobic core comprises liquid oil,
wherein lipids present in the hydrophobic core are in liquid phase at 25 degrees Celsius, and
wherein the DNA molecules are complexed to the cationic lipids to form DNA molecule-lipid nanoparticle complexes.